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A model for hepatic arterial chemotherapy studies using large dogs and an implantable infusion pump 
has been developed. Using this technique near complete perfusion (>90%) of the liver can be achieved 
in vivo as determined by hepatic arterial perfusion scintigraphy with technitium 99m macroaggregated 
albumin. The system is reliable and has been in use for a total of 1353 days (mean of 104 days, range 
52-239) in 13 dogs. Pump implantation causes no apparent acute liver damage based on pre- and post- 
operative alkaline phosphatase and serum glutamic-pyruvic transaminase determinations and does not 
affect the general mobility or behavior of the animals. Careful placement of the catheter and attention 
to the physicochemical properties of the solutions loaded are factors contributing to the success of the 
model. The model permits comprehensive preclinical pharmacokinetic and toxicologic studies of new 
or preexistent chemotherapeutic agents in the same device that will be used for later administration in 
human subjects. By providing the means to examine and develop new treatment modalities, it enables 
the design of even more potent cytotoxic therapy directed into the tumor vascular bed. 0 1986 Academic 
Press, Inc. 
INTRODUCTION 
A number of malignancies exhibit a ten- 
dency to remain confined to specific body 
areas or organs. In patients with these cancers, 
it is often not widespread metastasis but rather 
uncontrolled local tumor growth that is the 
primary cause of morbidity and eventual 
mortality. For regionally confined tumors such 
as primary and metastatic carcinomas involv- 
ing the liver, direct administration of che- 
motherapeutic agents into the hepatic artery 
potentially can generate increased regional 
drug exposure while maintaining systemic 
drug levels below the toxic threshold for the 
usual dose-limiting tissues [ 1,2]. This is espe- 
cially true for cancer within the liver since he- 
patic tumors derive 95% of their blood supply 
from the hepatic artery while two-thirds of the 
blood supply to the liver parenchyma comes 
from the portal vein [3-51. 
’ Supported in part by USPHS Grant CA-33825. 
’ To whom reprint requests should be addressed. 
Attempts to utilize this flow differential 
therapeutically have been plagued by a high 
rate of complications such as vessel throm- 
bosis, catheter dislocation, and infection and 
required the use of bulky external pumping 
devices [6-g]. Recent advances in the tech- 
nology of drug delivery systems, radionuclide 
angiography, and pharmacology have made 
possible safer, more reliable approaches to he- 
patic arterial chemotherapy and have renewed 
interest in its use [ 10, 111. The implantable 
Infusaid pump and catheter drug delivery sys- 
tem is being used increasingly for the regional 
administration of chemotherapy in cancer pa- 
tients on a chronic basis. For patients with 
cancer in the liver, the application of regional 
chemotherapy with this system appears to re- 
sult in markedly improved response rates and 
has perhaps impacted upon survival as well 
[12, 131. 
At the present time, however, the number 
of drugs and therapeutic modalities available 
for common use with the pump are extremely 
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limited. One of the major impediments to 
progress in this area has been the lack of a 
large animal model with which to pursue pre- 
clinical investigations. In this paper, we report 
the successful development of a canine model 
and describe some of the surgical considera- 
tions in its use. 
Once our model was established, the drug 
we administered through the implanted 
pumps was 5-bromo2’deoxyuridine (BUDR), 
a radiosensitizer with which we were perform- 
ing toxicologic studies in preparation for its 
use in this capacity with radiotherapeutic mi- 
crospheres. Recent studies suggest that tumors 
are often hypervascular compared to normal 
liver [ 14- 161. Regional microsphere therapies 
represent a means of capitalizing on this rel- 
ative tumor hypervascularity by generating a 
prolonged exposure of drug or radiation within 
tumor vessels. We intend to use our canine 
model to study the hepatic arterial adminis- 
tration of yttrium-90 microspheres as a means 
to deliver internal radiotherapy after pretreat- 
ment with a continuous regional infusion of 
radiation sensitizer. We anticipate that the re- 
sults of these and other investigations will pro- 
vide a basis for the application of microsphere 
administration and other selective modalities 
to the treatment of primary and metastatic 
liver cancer. Similar large animal models will 
serve to advance the use of such selective ap- 
proaches in other regionally confined malig- 
nancies such as brain tumors and head and 
neck cancer. 
lines; their weights were monitored monthly 
and their activity and appetite assessed at least 
daily. A technetium-99m sulfur colloid liver 
spleen scan and baseline laboratory studies 
consisting of serum glutamic-pyruvic trans- 
aminase (SGPT), alkaline phosphatase (AP), 
and amylase were obtained before pump im- 
plantation. These laboratory studies were re- 
peated weekly for 2 weeks after surgery and 
during periods of drug infusion. 
Drug delivery system. Infusaid Model 400 
implantable infusion pumps (Intermedics-In- 
f&aid, Norwood, Mass.) were placed into the 
13 dogs. A radiopaque, tapered, silicone rub- 
ber catheter (No. 36587, Intermedics-Infusaid) 
was chosen as its tapered end facilitated in- 
sertion into the artery. The catheter’s total 
length is 38-40 cm, the outer diameter (o.d.) 
2.3 mm tapering down to 1.5 mm and the 
inner diameter (i.d.) 0.6 mm throughout. 
Placement of beaded rings on the outside sur- 
face near the tip of the catheter aided both in 
accurate placement and in preventing catheter 
movement by providing points at which the 
soft tubing could be secured to the cannulated 
artery and to surrounding tissue. 
MATERIALS AND METHODS 
Prior to implantation each pump was 
loaded with 50 ml (maximum capacity) of 
sterile saline containing 100 U/ml of sodium 
heparin. Every 14 days, the residual chamber 
volume was emptied and measured, and the 
pumps refilled. Flow rates were calculated by 
subtracting the residual volume from 50 ml 
and dividing the remainder by 14. The baseline 
flow rates of individual pumps remained con- 
stant averaging 2.6 ml/day (range 2.0 to 3.2 
ml/day). 
Animals. Thirteen foxhounds with a mean 
weight of 32.1 kg (range 25-40 kg) were ob- 
tained from the Laboratory Animal Center of 
Ohio State University, Columbus, Ohio. The 
dogs were held in the Animal Research Facility 
of the University of Michigan for observation 
prior to undergoing any manipulations for this 
study. For the duration of the study, the ani- 
mals were quartered in and maintained by the 
University of Michigan Unit for Laboratory 
Animal Medicine according to DHHS Guid- 
Reuse of the pumps is possible. We rec- 
ommend first clearing all traces of prior con- 
tents by repeatedly loading the pump with 
sterile water and running it while immersed 
in a 56°C water bath. Once a pump is purged, 
its catheter can be replaced with an unused 
one attaching it with Silastic medical adhesive 
(Dow Corning Corp., Midland, Mich.). The 
pump and catheter can then be sterilized at 
110°C for 50 min. Should a pump lack a ta- 
pered catheter tip, one can be constructed by 
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fastening a smaller o.d. catheter onto the larger 
o.d. pump catheter using a barbed metal con- 
nector (No. 36590, Intermedics-Infusaid) and 
Silastic medical adhesive (see Fig. 1, inset). 
Operative techniques. Anesthesia was initi- 
ated with 400-500 mg sodium thiamylal (Sur- 
ital, Parke-Davis, Morris Plains, N.J.) and 
maintained via endotracheal intubation with 
a mixture of 02, N20, and nalothane. All dogs 
received gentamycin sulfate (Garamycin, 
Schering Corp., Indianapolis, Ind.), 500 mg 
im BID on the day of surgery and sodium ce- 
fazolin 500 mg im BID for 4 days postoper- 
atively. 
The pump was placed in a subcutaneous 
pocket created approximately 10 cm from the 
dorsal midline and sutured to the underlying 
muscle using at least three of the five loops 
permanently attached to the pump’s circum- 
ference for this purpose. The dorsal location 
was chosen because placement ventrally 
within the abdominal wall resulted in poor 
wound healing and pump movement in these 
active animals. 
The first catheter placement attempted (two 
dogs) was insertion into the gastroduodenal 
FIG. 1. Catheter placement in the canine common he- 
patic artery. The gastroduodenal artery is ligated. The inset 
shows the modified, beaded catheter. This placement re- 
sulted in consistently greater liver perfusion. 
artery as this is similar to the technique most 
commonly used clinically in patients [ 181. 
Upon exposure, the gastroduodenal artery was 
ligated distally. The catheter tip was then in- 
serted through a small arteriotomy, positioned 
l-2 mm from the origin, and secured by a 
2-O black silk ligature. 
In four dogs a second site was chosen for 
placement. The catheter tip was inserted 
through a small arteriotomy in the splenic ar- 
tery and advanced until the tip was flush with 
the celiac axis. The splenic, left gastric, and 
gastroduodenal arteries were then ligated and 
the catheter was secured. 
The site ultimately selected for catheter 
placement (seven dogs) was the common he- 
patic artery. After introduction via arteriot- 
omy, the catheter tip was positioned approx- 
imately 1.5 cm distal to the origin of the left 
gastric artery and secured so as not to occlude 
arterial flow. The gastroduodenal artery was 
then ligated. 
Flow distribution. Liver-spleen scans were 
obtained on all dogs using 4 mCi of technitium 
sulfur colloid prior to pump implantation. 
Hepatic arterial perfusion scans (HAPS) 
were performed by slow injection of 4 mCi 
of technitium macroaggregated albumin 
(TcMAA) through the sideport of the pump 
soon after implantation [ 111. The percentage 
of liver substance perfused was estimated by 
visually comparing the anterior, posterior, and 
lateral aspects of the liver-spleen scan with 
similar views obtained with the HAPS. Using 
these images, shunting of blood to the lungs 
and other extrahepatic locations could be de- 
tected. Any animals exhibiting these findings 
would have been excluded from involvement 
in the drug study. In seven dogs, the pattern 
of distribution was reassessed 3 months after 
the original determination by a repetition of 
the HAPS. 
Drug solutions. 5-Bromo-2’-deoxyuridine 
(BUDR) Lot No. 416900 was obtained from 
P-L Biochemicals, Inc., Milwaukee, Wiscon- 
sin. Purity was >98% by spectral analysis and 
no contaminating substances were found by 
thin-layer chromatography using two solvent 
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systems. A solution containing 500 mg/ml of 
BUDR in a 0.1 M sodium bicarbonate/car- 
bonate buffer (pH 9.8 + 0.1) was prepared. 
Stability of this BUDR buffer solution at 37°C 
was satisfactory with ~5% decrease in BUDR 
concentration by high-performance liquid 
chromatographic analysis over 14 days (in 
glass or the pumps). This stock solution was 
then diluted further so that BUDR at a dose 
of 10 mg/kg/day was delivered over 14 days 
through the pump to each of five dogs. These 
dogs received two consecutive 1Cday infu- 
sions to achieve a 28day continuous exposure 
to the drug. Five control animals received an 
infusion of the 0.1 M buffer solution without 
BUDR for the same time period. Three dogs 
received 2 weeks of BUDR followed by 2 
weeks of control buffer solution. Upon ter- 
mination of BUDR infusions, control buffer 
solution was instilled into the pumps of treat- 
ment animals. Heparin, at a concentration of 
1000 units of heparin per milliliter, was added 
to all solutions. Three additional dogs received 
1Cday infusions of 10 mg/kg/day BUDR al- 
ternating with 1Cday infusions of control 
buffer solution. 
RESULTS 
As we confirmed by preoperative angiog- 
raphy (Fig. 2), the arterial anatomy of the dog 
varies considerably from human vascular pat- 
terns, and therefore three successive variations 
in catheter placement were required to obtain 
one providing complete (90- 100%) liver per- 
fusion consistently. Estimates of the percent- 
age of liver perfused for every dog with each 
of the variations of catheter placement are 
listed in Table 1. Once experience was ac- 
quired with the technique, the most complete 
perfusions were obtained with catheter inser- 
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FIG. 2. A presurgical an&gram in a dog demonstrating typical canine vascular anatomy in this region. 






































’ This dog died before perfusion extent could be deter- 
mined (See Results). 
parison of the sulfur colloid image in Fig. 3a 
with the corresponding TcMAA HAPS image 
(Fig. 3b) illustrates a liver with only 40% per- 
fusion. By comparing Fig. 3c with Fig. 3d, a 
>90% perfusion pattern will be seen. 
In addition to yielding an inadequate per- 
fusion pattern, use of the splenic artery resulted 
in the death of one dog. Ligation of the splenic, 
left gastric, and gastroduodenal arteries and 
some constriction of the proper hepatic artery 
led to severe hemorrhagic, ischemic necrosis 
of the spleen, stomach, duodenem, jejunum, 
and the left lateral and left medial lobes of the 
liver. Subsequently, considerable care has been 
taken to ensure that ligation of the gastroduo- 
denal artery does not constrict the proper he- 
patic artery. Catheter placement during sur- 
gery is the most critical step in assuring that 
the entire liver will be safely perfused with drug 
solution from the implanted pump [ 171. 
The implanted pumps have operated sat- 
isfactorily for a total of 1353 days (mean 104, 
range 52-239) in the 13 dogs. Each pump was 
refilled an average of seven times with no 
complications. To assess the patency of the 
vessel and catheter and the distribution of flow 
over time, TcMAA perfusion scans were re- 
peated approximately 3 months after the orig- 
inal flow determinations on 7 of the 13 dogs. 
The change in the volume of liver perfused in 
these animals was less than 10%. The viscosity 
of the BUDR solution resulted in flow rates 
that were 33% of those obtained using control 
buffer solution (Table 2). Patency of the cath- 
eters was unaffected by the altered viscosity 
during the BUDR infusions. 
No significant difference between pre- and 
postsurgery levels of hepatic enzymes (SGPT 
or AP) could be found by t test. The postop 
erative amylase levels, however, were higher 
(significant at the 0.05 level) suggesting the 
possibility of some pancreatic ischemia al- 
though they were still within the normal range 
and the animals remained clinically well. Dogs 
receiving 4 weeks of control buffer solution 
and those given only 2-week infusions of 
BUDR demonstrated no significant elevations 
in liver function tests while those animals 
given 28 days of BUDR developed significant 
elevations after the third week (Table 3). 
DISCUSSION 
Hepatic arterial chemotherapy represents a 
means to improve antitumor effect by in- 
creasing drug exposure to tumor within the 
liver relative to the exposure of the dose-lim- 
iting tissues elsewhere in the body. Because of 
the idea’s attractiveness, many attempts to ap- 
ply it have been reported in the medical lit- 
erature during the past 20 years. Until recently, 
however, use of this technique was hampered 
by a high incidence of partial or complete ves- 
sel thrombosis, catheter displacement, infec- 
tion, and other complications [6-91. 
Recent advances in the technology of drug 
delivery systems, radionuclide angiography, 
and pharmacology have made possible safer, 
more reliable approaches to hepatic arterial 
chemotherapy and have renewed interest in 
its use. The implantable Infusaid pump and 
catheter drug delivery system is being used in- 
creasingly for the regional administration of 
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FIG. 3. (a) Right Lateral view of a standard Tc-sulfur colloid liver-spleen scan in the foxhound whose 
perfusion study is shown in Fig. 3b. (b) Right Lateral view of a hepatic arterial perfusion scan (HAPS) from 
the dog whose liver-spleen scan is shown in Fig. 3a. Liver perfusion in this dog was approximately 40%. (c) 
Right Lateral view of a standard Tc-sulfur colloid liver-spleen scan of the dog whose perfusion scan is shown 
in Fig. 3d. (d) Right Lateral view of the HAPS from the dog whose liver-spleen scan is shown in Fig. 3c. 
Liver perfusion in this dog was approximately 90%. The circular area of tracer activity in the Lower-Left 
hand comer is the injection site (pump side-port). 
chemotherapy in cancer patients on a chronic 
basis. For patients with primary and metastatic 
carcinomas within the liver, the application of 
TABLE 2 
BUDR INFUSION 
Initial BUDR BUDR BUDR 
wt flow Flow Concn dose 
(kg) (ml/day) (ml/W bw/ml) W/kg/~y) 
36 2.6 0.8 461.5 10.2 
28 2.3 0.7 404.0 10.2 
28 2.9 1.1 326.3 13.2 
34 3.2 1.1 357.5 11.2 
31 2.9 0.9 356.3 10.7 
31 2.3 1.3 169.4 1.4 
27 2.4 1.6 139.2 8.3 
37 2.0 1.0 266.2 1.3 
regional chemotherapy with this system has 
resulted in reports of markedly improved re- 
sponse rates and perhaps has impacted upon 
survival [ 12, 131. At the present time, however, 
the number of drugs and therapeutic modal- 
ities available for common use with the pump 
are extremely limited. 
One of the major impediments to progress 
in this area has been the lack of a large animal 
model with which to pursue preclinical testing 
involving the implanted device. With this pa- 
per, we report the successful development of 
just such a canine model. That the optimal 
catheter placement in the model would differ 
significantly from the position most com- 
monly used clinically was unexpected. We 
have experienced no difficulty maintaining 
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TABLE 3 
LIVER FIJNCXON TEST CHANGES IN THREE GROUPS OF DOGS: THOSE RECEIVING 28 CONSECUTIVE DAYS OF 
BUFFER ALONE, 14 DAYS OF BUDR FOLLOWED BY 14 DAYS OF BUFFER, AND 28 CONSECUTIVE DAYS 
OF BUDR, ALL SOLUTIONS ADMINISTERED BY CONTINUOUS HA INFUSION VIA IMPLANTED FWM~~ 
Group Day 0 7 14 21 28 
Alkaline phosphatase 
28day buffer 4.7 4.1 3.4 3.3 3.0 (Bodansky Units/d]) 
NL 1.7-9.7 range 
14-day BUDR/ 14-day buffer 60.9 56.4 71.0 59.8 58.9 (U/L) NL range 29.7- 
87.3 
28&y BUDR 5.0 4.5 3.6 4.0 7.5 (Bodansky Units/dL) 
Serum glutamic pyruvic transaminase (IU/L) 
28day buffer 27.0 21.5 25.3 14.2 22.5 (NL Range 10.9-38.5) 
14day BUDR/ 14day buffer 28.9 33.0 42.2 30.5 29.2 
28day BUDR 22.7 22.2 24.6 44.2 72.6 
catheter patency in this location, however, and 
have not witnessed a rise in residual chamber 
volume with a decline in flow rate of individual 
pumps as would occur with gradual thrombus 
formation. Consistent with common clinical 
practice, we added heparin to all solutions in- 
fused. Since we did not have an unheparinized 
comparison group, we are unable to determine 
the role and importance, if any, that heparin 
has in maintaining vessel and catheter patency. 
With the development of this model, it now 
will be possible to perform comprehensive 
preclinical pharmacokinetic and toxicologic 
studies of new or preexistent chemotherapeu- 
tic agents in the same device that will be used 
for later administration in human subjects. For 
example, we have used the model to explore 
the effect of dose schedule on toxicity from 
hepatic arterial BUDR infusion as a prelude 
to combining the radiosensitizing infusion 
with the regional administration of radiother- 
apeutic microspheres. Without subjecting hu- 
man patients to any risks or discomforts, we 
were able to determine that BUDR can cause 
a schedule-dependent chemical hepatitis sim- 
ilar to that seen clinically with FUDR [ 12, 131. 
This model thus provides the means to ex- 
amine, develop, and integrate new treatment 
modalities such as degradable starch and non- 
degradable radiotherapeutic microspheres, 
vasoconstrictors, and radiosensitizers such as 
BUDR. Through such use, this model will en- 
able the design of even more potent cytotoxic 
therapy to direct into the tumor vascular bed. 
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